Vanguard Portfolio Management
PTCT icon

Vanguard Portfolio Management’s PTC Therapeutics PTCT Stock Holding History

Vanguard Portfolio Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$402M Buy
4,928,111
+123,517
+3% +$8.92M 0.02% 818
2026
Q1 		$327M Buy
+4,804,594
New +$340M 0.02% 851

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Vanguard Portfolio Management's PTCT Position: Q2 2026 in Review

Vanguard Portfolio Management increased its PTC Therapeutics (PTCT) stake by 2.6% in Q2 2026, buying an estimated $8.92M and bringing the position to 4,928,111 shares worth $402M. The position accounts for 0.02% of the portfolio, ranked #818.

Vanguard Portfolio Management first reported a position in PTCT in Q1 2026 and has held it in 2 quarters since. 374 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Vanguard Portfolio Management held 4,928,111 shares of PTC Therapeutics worth $402M as of Q2 2026.
  • Vanguard Portfolio Management bought 123,517 PTC Therapeutics shares in Q2 2026, an estimated $8.92M.
  • PTC Therapeutics made up 0.02% of Vanguard Portfolio Management's portfolio in Q2 2026, its #818 holding.
  • Vanguard Portfolio Management first reported a position in PTC Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 374 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.